CareDx's Growth Prospects With Naveris Keep Me Bullish

CareDx has a transplant-testing franchise that taps into recurring surveillance demand and has deeper integration into transplant centers. I also think CDNA’s AlloHeme gives them longer-term optionality in post-cell-therapy monitoring. More recently, CDNA sold Lab Products and purchased Naveris. These major strategic M&A deals mean CDNA now has a potential growth engine in oncology. However, I reckon CDNA’s valuation is relatively expensive. But despite that concern, I think its long-term growth justifies the stock as a speculative “Buy” today. CareDx, Inc. ( CDNA ) develops blood-based tests and digital tools to help monitor patients with complex health conditions. The company mainly serves organ-transplant recipients, offering tests that help doctors check for graft injury and rejection, reducing